Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial.

Werth, Sebastian; Bauersachs, Rupert; Gerlach, Horst; Rabe, Eberhard; Schellong, Sebastian; Beyer-Westendorf, Jan

Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial.

Werth, Sebastian; Bauersachs, Rupert; Gerlach, Horst; Rabe, Eberhard; Schellong, Sebastian; Beyer-Westendorf, Jan.

Afiliação

Werth S; Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital "Carl Gustav Carus", Technical University Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Bauersachs R; Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany.
Gerlach H; Center of Thrombosis and Hemostasis, University of Mainz, Mainz, Germany.
Rabe E; Private Office for Vascular Diseases, Mannheim, Germany.
Schellong S; Department of Dermatology, University of Bonn, Bonn, Germany.
Beyer-Westendorf J; Medical Department II, Dresden Friedrichstadt Hospital, Dresden, Germany.

J Thromb Thrombolysis ; 42(2): 197-204, 2016 Aug.

Article em En | MEDLINE | ID: mdl-26973347

Assuntos

Polissacarídeos/uso terapêutico; Rivaroxabana/uso terapêutico; Trombose Venosa/tratamento farmacológico; Progressão da Doença; Fondaparinux; Humanos; Recidiva; Medição de Risco; Método Simples-Cego; Resultado do Tratamento; Tromboembolia Venosa/tratamento farmacológico; Trombose Venosa/complicações

Palavras-chave

Fondaparinux; Rivaroxaban; Superficial vein thrombosis; Thrombophlebitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polissacarídeos / Trombose Venosa / Rivaroxabana Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google